Annals of Indian Academy of Neurology
ORIGINAL ARTICLE
Year
: 2022  |  Volume : 25  |  Issue : 3  |  Page : 441--448

Covid-19 and mucormycosis superinfection: Prospective, obsevational study in a single center


Shubham Garg, Dilip Masheshwari, Bharat Bhushan, Vijay Sardana, Raj Kumar Jain 
 Department of Neurology, MBS Hospital Main Station Road, Nayapura, Kota, Rajasthan, India

Correspondence Address:
Shubham Garg
Flat 103 Inika Residency Civil Lines Nayapura Main Station Road, Kota, Rajasthan
India

Background: Mucormycosis (MCR) has been increasingly described in patients with coronavirus disease 2019 (COVID-19), but the epidemiological factors, neurological presentation, and outcome of such patients are not well described. Aims: To study the patient demographics, presenting symptoms and signs, the role of co-morbidities, medications used to treat COVID-19, and the outcomes of management and to study the spectrum of neuraxis involvement and its outcome. Methods: It was a prospective, observational, cross-sectional hospital-based single center cohort study. Confirmed MCR cases with and without COVID-19 were collected. The study was carried out over a period of 3 months from May to July 2021, followed by 3-month follow-up. Information on epidemiological factors, neurological findings, treatment (including medical and surgical treatment), and outcome was recorded. Results: A total of 141 patients were diagnosed with MCR, out of which 98 were COVID-associated MCR (CAM). The CAM incidence was 0.39% among COVID-19-positive patients. The MCR case fatality rate at 90 days was 43.9% but was higher for CAM than for non-CAM patients. Older ages (>50 years), diabetes mellitus, multiple risk factors, diabetic ketoacidosis on admission, brain involvement, and history of COVID-19 pneumonitis were associated with a higher risk for death. Conclusions: Possibly because of improper usage of corticosteroids, zinc, oxygen, and tocilizumab, there was sudden surge of cases of MCR in the COVID-19 pandemic. Therefore, treating physicians should use the COVID-19 pneumonia regimen judiciously. Neurological involvement itself is a poor prognostic sign, but combined surgical and medical management exhibited better outcome.


How to cite this article:
Garg S, Masheshwari D, Bhushan B, Sardana V, Jain RK. Covid-19 and mucormycosis superinfection: Prospective, obsevational study in a single center.Ann Indian Acad Neurol 2022;25:441-448


How to cite this URL:
Garg S, Masheshwari D, Bhushan B, Sardana V, Jain RK. Covid-19 and mucormycosis superinfection: Prospective, obsevational study in a single center. Ann Indian Acad Neurol [serial online] 2022 [cited 2022 Sep 26 ];25:441-448
Available from: https://www.annalsofian.org/article.asp?issn=0972-2327;year=2022;volume=25;issue=3;spage=441;epage=448;aulast=Garg;type=0